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Full Activation of RNaseL in Animal Cells Requires 
Binding of 2-5A Within Ankyrin Repeats 6 to 9 of This
Interferon-Inducible Enzyme
MARGARITA DÍAZ-GUERRA,1,2 CARMEN RIVAS,1 and MARIANO ESTEBAN1
ABSTRACT
To define protein domains important for activation of the interferon (IFN)-induced enzyme 2-5A-dependent
RNaseL, we have generated vaccinia virus (VV) recombinants able to express in cultured cells truncated forms
of this protein and compared their biologic activities with those producing the wild-type enzyme, with and
without coexpression of 2-5A synthetase. Our results show that full activation of RNaseL requires binding of
2-5A oligonucleotides within amino acid positions 212± 339, corresponding to ankyrin repeats 6 to 9. The pro-
tein kinase and ribonuclease domains of RNaseL, amino acids 340± 741, are sufficient for a constitutively ac-
tive enzyme that is unresponsive to excess 2-5A. These results demonstrate in vivo the importance of the
ankyrin domains in the biologic function of RNaseL. We suggest that ankyrin repeats act as key modulators
of RNaseL activity.
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INTRODUCTION
ENDORIBONUCLEASE L (RNASEL) is an interferon (IFN)-in-ducible enzyme (reviewed in refs. 1±3) present in mam-
malian cells as a component of the 2-5A system, an IFN-regu-
lated RNA degradative pathway.(4) Other proteins in this system
are the double-stranded (ds)-RNA activated synthetases that
produce 59 -triphosphorylated oligoadenylic acid (referred to as
2-5A) that binds to and activates RNaseL.(1) During virus in-
fection, dsRNA is frequently produced, and activation of the 2-
5A pathway is one of the mechanisms used by IFN to inhibit
virus multiplication (reviewed in refs. 1, 5), directly demon-
strated in the case of picornaviridae,(6±8) vaccinia virus (VV),(9)
and human immunodeficiency virus-1 (HIV-1).(10) The biologic
significance of the 2-5A system probably goes beyond its an-
tiviral activities, and it has been suggested that enzymes in this
pathway also have tumor-suppressor activities.(11) In this re-
gard, the recent findings that activation of RNaseL causes death
of cells by apoptosis(12±14) might be a mechanism mediating
anticellular and antiviral actions of IFN.
Sequence analysis of human RNaseL gene(15) has shown that
this protein is composed of three functional domains. At the N
terminus are nine ankyrin-like repeats, immediately followed
by a complete protein kinase domain and next to it, in the C
terminus, the residues where the endoribonuclease activity is
located.(16,17) A truncated form of RNaseL lacking 89 amino
acids at the C-terminus but still capable of 2-5A binding be-
haves as a dominant negative mutant in stable cell lines.(17)
Ankyrin repeats are about 33 amino acids long and have been
involved in mediating interactions in many different types of
proteins (reviewed in refs. 18, 19). Interestingly, the catalyti-
cally active form of purified recombinant 2-5A-dependent
RNaseL is a homodimer that forms only on binding to 2-5A.(20)
Recently, a novel bifunctional protein kinase/endoribonuclease
(Ire1p) was found in mammalian cells,(21) which, similarly to
its homolog in Saccharomyces cerevisiae,(22) is an essential
proximal sensor of the unfolded protein response pathway
(UPR). The C-termini of these proteins present significant se-
quence similarity to the endoribonuclease domain of human
RNaseL.(21,22)
To learn about the structural-functional relationship of
ankyrin domains in RNaseL, in this investigation we have stud-
ied the biologic function of truncated forms in vivo by using an
expression system based on VV recombinants able to produce
in mammalian cells enzymes in the 2-5A pathway that are ac-
tive.(9,13) Our findings provide the first in vivo mapping of func-
tional domains of RNaseL and strongly suggest that the ankyrin
repeats constitute key modulators of RNaseL activity.
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MATERIALS AND METHODS
Plasmids
Human RNaseL gene contained in ZC-5 plasmid(15) was
kindly provided by Robert H. Silverman (Cleveland Clinic
Foundation, Cleveland, OH). We generated plasmid pRSET-
RL for expression of RNaseL in Escherichia coli as de-
scribed.(9) It contains the coding sequence for RNaseL, lacking
only nucleotides coding for the 21 amino acids at the N-termi-
nus, fused to a sequence for 38 new amino acids that includes
a stretch of 6 histidine residues and the first 12 amino acids of
the bacteriophage T7 gene 10 leader peptide. We generated
plasmid pRSET-N by Nco I digestion of pRSET-RL and reli-
gation. This plasmid is similar to pRSET-RL but lacks se-
quences coding for amino acids 228±741 of RNaseL. Plasmid
pRSET-1S and pRSET-2S were generated by SacI digestion of
pRSET-Rl and religation. The former encodes a protein differ-
ing from the product of pRSET-Rl in a deletion of amino acids
212±339 in RNaseL sequence. In pRSET-2S, the deletion is of
amino acids 22±339. Plasmid pTM- D N was obtained by cloning
an NdeI 1 NcoI DNA fragment from pRSET-N into the SmaI
site of VV insertion vector pTM 1-E.(23) Similarly, we obtained
plasmids pTM-RL, pTM- D 1S, and pTM-D 2S by subcloning an
NdeI DNA fragment from corresponding constructs in pRSET-
B into the same insertion vector. These plasmids contain se-
quences coding for 8 extra amino acids in the N terminus in
front of the initiation codon provided by pRSET-B. Plasmid
pSC-2-5AS was obtained as described(9) and contains the E.
coli b -galactosidase gene (lac z) under the control of a late vi-
ral promoter (p11) and human 40 kDa 2-5A synthetase gene
under the control of an early and late viral promoter (p7.5).
Cells and viruses
African green monkey kidney cell line BSC-40 was grown
in Dulbecco’s modified Eagle’ s medium (DMEM) supple-
mented with 10% newborn calf serum. Cells were cultivated at
37°C with 5% CO2. The recombinant viruses VV-RL, VV- D N,
and VV-2-5AS were obtained as described by introduction of
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FIG. 1. Diagram of plasmid vectors for the expression of truncated forms of RNaseL by VV recombinants. The structures of
the insertion plasmids pTM-RL, pTM-D 1S, pTM-D 2S, and pTM- D N used to generate VV recombinants are shown. pT7, bacte-
riophage T7 polymerase promoter; EMC, encephalomyocarditis virus sequences for cap-independent translation; MCS, multiple
cloning site; solid boxes, pRSET-B sequences comprising an ATG, 6 histidine residues, and the gene 10 leader peptide; open
circles, ankyrin-like repeats in 2-5A-dependent RNaseL; gray oval, protein kinase homology region; gray rectangle, region re-
quired for RNase activity; Ter, T7 transcriptional terminator. Numbers correspond to amino acid positions in human RNaseL se-
quence. Other relevant regions in pTM1-E insertion vector are also shown.
the insertion plasmids pTM-RL, pTM-N, and pSC-2-5AS, re-
spectively, into the thymidine kinase (tk) region of wild-type VV
(WR) by homologous recombination.(9) Using a similar proce-
dure, we obtained recombinant viruses VV-D 1S and VV- D 2S.
Basically, plasmids pTM-1S and pTM-2S were transfected into
BSC-40 cells using lipofectamine reagent (GIBCO BRL, Paisley,
UK) as indicated by suppliers, and recombinant viruses were se-
lected in human TK-143B cells using 59 -bromo-deoxyuridine (25
m g/ml).(24) Three rounds of plaque purification in this cell line
yielded homogeneous virus preparations containing the desired
genes, as confirmed by Southern blot DNA hybridization analy-
sis. Expression of proteins RNaseL, RNaseL-D 1S, RNaseL-D 2S,
and RNaseL-D N, produced by viruses VV-RL, VV- D 1S, VV-
D 2S, and VV-N, respectively, is under the control of a T7 pro-
moter. The recombinant proteins contain at the N-terminus 46 ad-
ditional amino acids, including a stretch of 6 histidine residues
and the 12 amino acids gene 10 leader peptide.(9) Other TK viruses
vTF7-3 (herein vT7)(25,26) and VV-LUC,(27) were as described.
Analysis of low-molecular weight DNA
Low-molecular weight DNA was isolated(28) from cultured
cells infected with the different VV recombinants under condi-
tions described in Figure 4. The DNA was analyzed by 1.6%
agarose gel electrophoresis, and it was visualized by staining
with ethidium bromide.(13)
Total RNA isolation
Total cellular RNA from infected cells was isolated using
the Ultraspec-II RNA Resin Purification System (Biotecx). For
analysis, denatured RNA was fractionated on 1% formalde-
hyde-agarose gels and stained using ethidium bromide.(13)
Analysis of protein synthesis
For immunoblot analysis, protein samples were fractionated
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to nitrocellulose paper in a semidry blotting appa-
ratus for 45 min at 200 mA and analyzed by immunoperoxi-
dase staining after reactivity with different sera. Rabbit poly-
clonal serum specific for RNaseL was prepared as described.(9)
Monoclonal anti-T7 tag antibody (Novagen, Madison, WI) rec-
ognizing the gene 10 leader peptide in the N-terminus of fu-
sion proteins was used at a 1:3000 dilution. Rabbit polyclonal
serum was specific for 2-5A synthetase was kindly provided by
Robert H. Silverman (Cleveland Clinic Foundation). Analysis
of de novo protein synthesis was performed by labeling for the
specified times with [35S]-labeled methionine 1 cysteine (100
m Ci/ml) in methionine and cysteine-free medium. After wash-
ing with phosphate-buffered saline (PBS), cells were immedi-
ately collected in lysis buffer, extracts were fractionated in SDS-
PAGE, and dried gels were autoradiographed.
RESULTS
Generation of VV recombinants expressing truncated
forms of RNaseL
To investigate the structural-functional relationship of the
ankyrin domains, we generated recombinants expressing trun-
cated forms of RNaseL and analyzed them compared with full-
length enzyme (diagram of vectors in Fig. 1). Viruses VV- D 1S
and VV- D 2S were obtained by homologous recombination of
insertion vectors pTM-D 1S and pTM- D 2S, containing, respec-
tively, RNaseL coding sequence lacking amino acids 212±339
or 1±339 into VV tk gene.(24) Recombinant viruses VV-RL,
producing nearly full-length RNaseL, and VV- D N, expressing
a truncated RNaseL lacking amino acids 228±741, were de-
scribed previously.(9) After three cycles of virus purification,
the recombinant viruses were confirmed by Southern blot DNA
hybridization (data not shown). To define protein expression,
monkey kidney BSC-40 cells were infected with 2 pfu/cell of
each recombinant VV and at 24 h after infection, cells were la-
beled with [35S]-methionine-cysteine for 2 h, and the protein
pattern was analyzed by SDS-PAGE and autoradiography. As
shown in Figure 2A, all recombinant viruses induced proteins
of expected size for wild-type RNaseL and truncated forms,
RNaseL-D 1S (Mr 68 kDa), RNaseL-D 2S (Mr 45 kDa), and
RNaseL-D N (Mr 25 kDa). Because RNaseL genes were under
the control of bacteriophage T7 promoters, proteins corre-
sponding to different fragments were only obtained by coin-
fection of monkey kidney BSC-40 cells with a second recom-
binant virus (vTF7-3, herein vT7) that contains a T7 polymerase
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FIG. 2. Expression by VV recombinants of truncated forms
of RNaseL in cultured cells. Monolayers of BSC-40 cells were
infected with VV-2-5AS (moi 4 pfu/cell, lane 2) or doubly in-
fected with vT7 1 VV-RL (lane 3), vT7 1 VV- D N (lane 4),
vT7 1 VV- D 1S (lane 5), or vT7 1 VV- D 2S (lane 6) (moi 2
pfu/cell of each virus) for 24 h. Cells were labeled with [35S]-
methionine-cysteine for 2 h, and equal amounts of cell extracts
(30 m g) were fractionated in SDS-10% polyacrylamide gels and
analyzed by autoradiography (A) or by immunoblot, after trans-
fer of proteins to nitrocellulose paper and reactivity with a rab-
bit polyclonal serum against RNaseL (B). Lane 1, uninfected
cells.
gene under the control of VV constitutive promoter p7.5.(25) As
previously described,(9) expression of wild-type RNaseL in-
duces severe inhibition of viral and cellular protein synthesis
(Fig. 2A, lane 3). Significantly, protein synthesis was differen-
tially inhibited in cells infected with the mutant forms of
RNaseL compared with wild-type enzyme or with cells infected
with VV-2-5AS. The upper band in lane 2 (Fig. 2A) corre-
sponds to b -galactosidase, whose gene is not present in the other
VV recombinants under control of the T7 promoter. The iden-
tity of the recombinant proteins was confirmed by immunoblot
analysis using rabbit polyclonal anti-RNaseL serum (Fig. 2B).
The band intensities are different probably because of differ-
ences in binding of the antiserum, as the levels of protein ex-
pression were the lowest in cells infected with VV-RL.
The ankyrin region of RNaseL is required for 
full endoribonuclease and translation inhibition 
activities, and the sequences responsible map to
ankyrin repeats 6 to 9
We have shown previously that at late times of infection,
VV-RL causes the characteristic pattern of rRNA degradation
that is indicative of RNaseL activation, as well as inhibition of
virus protein synthesis(9) and cell death by apoptosis.(13) Com-
bined expression of RNaseL with human 40 kDa 2-5A syn-
thetase, produced by recombinant virus VV-2-5AS, further en-
hances the effects produced by RNaseL.(13) To establish the
importance of the ankyrin repeats in the biologic activity of
RNaseL, monolayers of BSC-40 cells were infected with one
VV recombinant expressing a truncated form of RNaseL in
combination with vT7 or VV-2-5AS or both, using 2 pfu/cell
of each virus. A total multiplicity of 6 pfu/cell was maintained
all along the experiment by using an auxiliary recombinant virus
VV-LUC,(27) which is, as other recombinants used in this work,
a tk( 2 ) virus. We extracted total cellular RNA 48 h after in-
fection in order to perform rRNA degradation assays (Fig. 3A).
In an attempt to quantify the endonuclease activity of the dif-
ferent forms of RNaseL, we have taken the amount of 28S
rRNA found in cells infected with vT7 1 VV- D N (Fig. 3A, lane
4) as 100%, considering that cleavage is not observed in this
situation. Because 2-5A accumulates at late times during VV
infection,(29,30) recombinant RNaseL becomes active in vT7 1
VV-RL-infected cells, and severe cleavage is observed (Fig.
3A, lane 2), resulting in only 5.9% of the amount of 28S rRNA
recovered in control cells. Interestingly, proteins RNaseL-D 1S
(Fig. 3A, lane 6) and RNaseL- D 2S (Fig. 3A, lane 8) are also
active and produce a characteristic pattern of rRNA fragments.
The amount of 28S rRNA found was, respectively, 35.3% and
21.2% of values obtained in cells expressing RNaseL- D N. From
this experiment, we conclude that truncated forms of RNaseL
lacking up to 339 amino acids at the N-terminal region, which
correspond to deletions of the ankyrin domain, still have en-
donuclease activity.
Coexpression of recombinant 2-5A synthetase further en-
hances RNaseL ribonuclease activity (Fig. 3A, compare lanes
2 and 3), and the amount of 28S rRNA recovered is further re-
duced to 2.3% of control values. At 48 hr after infection, cleav-
age of rRNA also could be observed in cells infected singly
with VV-2-5AS (Fig. 3A, lane 1), probably because of low lev-
els of activation of endogenous RNaseL, and only 13.5% of
28S rRNA was recovered. Synthesis of RNaseL-D 1S, D 2S, or
D N together with 2-5A synthetase modulates somehow the 2-
5A pathway, as there is a decrease in cleavage of rRNA rela-
tive to cells producing only 2-5A synthetase (Fig. 3A, compare
lanes 1 with lanes 5, 7, and 9). It is noteworthy that coexpres-
sion of 2-5A synthetase with RNaseL-D 1S (Fig. 3A, lane 7) or
RNaseL-D 2S (Fig. 3A, lane 9) does not significantly enhance
the level of RNA fragmentation produced (Fig. 3A, lanes 6 and
8, respectively) as occurs for the full-length enzyme. The
amount of 28S rRNA recovered in cells infected with vT7 1 VV-
D 1S1 VV-2-5AS or vT71 VV- D 2S1 VV-2-5AS was 25.9%
and 14.7% of control values, compared with 35.3% and 21.2%
obtained, respectively, if 2-5A synthetase is not produced. Im-
munoblot analysis with a rabbit polyclonal sera specific for 2-
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FIG. 3. Endoribonuclease activity and inhibition of protein
synthesis on coexpression of truncated forms of RNaseL with
2-5A synthetase. Monolayers of BSC-40 cells were infected
with the indicated combinations of viruses vT7, VV-RL, VV-
D 1S, VV- D 2S, VV- D N, and VV-2-5AS (moi 2 pfu/cell of each
virus). Total multiplicity was maintained at 6 pfu/cell at all
times using VV-LUC when required. (A) Analysis of RNA
degradation. Total RNA was purified using the Ultraspec-II
RNA Resin Purification System (Biotecx), and the amount of
RNA corresponding to 3 3 105 cells was fractionated in 1%
agarose-formaldehyde gels and stained with ethidium bromide.
Abundant RNA, 28S and 18S rRNA, are indicated. (B) Ex-
pression of 2-5A synthetase. Cell extracts (50 m g) were frac-
tionated in SDS-10% polyacrylamide gels, transferred to nitro-
cellulose, and immunoblotted using rabbit polyclonal sera
specific for 2-5A synthetase. (C) De novo protein synthesis.
Monolayers were infected for 24 h as before and labeled with
[35S]methionine1 cysteine (100 m Ci/ml) for 15 min as de-
scribed. Protein extracts (50 m g) were fractionated, and dried
gels were autoradiographed. The lane numbers at the bottom
refer to A, B, and C.
5A synthetase (Fig. 3B) demonstrated synthesis of this enzyme
in cells infected with VV-2-5AS, although the levels differed
depending on the specific effect on protein synthesis of the form
of RNaseL coexpressed.
A consequence of fragmentation of rRNA by activation of
the 2-5A pathway is inhibition of protein synthesis. Thus, we
analyzed de novo synthesis of proteins 24 h after infection (Fig.
3C), a time when production of virus proteins is still active,
whereas cellular protein synthesis is blocked.(31) Monolayers of
BSC-40 cells infected as before were pulse-labeled with [35S]-
methionine-cysteine (100 m Ci/ml) for 15 min in methionine and
cysteine-free medium, and protein extracts were fractionated in
SDS-polyacrylamide gels. Very low level of protein synthesis
activity was obtained in cells expressing RNaseL (Fig. 3C, lane
2), which was further reduced by coexpression of 2-5A syn-
thetase (Fig. 3C, compare lanes 2 and 3). However, expression
of 2-5A synthetase had no direct effect on protein synthesis by
itself at this time of infection, as already described (Fig. 3C,
lane 1). Cells infected with vT7 1 VV- D N presented protein
levels that were similar in the absence or presence of 2-5A syn-
thetase (Fig. 3C, lanes 4 and 5). The difference in protein syn-
thesis observed for VV-2-5AS (lane 1) and vT7 1 VV- D N (lane
4) infected cells is probably due to increased expression of
genes driven by polymerase T7 over VV promoters, as this ef-
fect was not observed in cells infected with VV-LUC (not
shown). Interestingly, in cells infected with recombinant viruses
VV- D 1S (Fig. 3C, lane 6) and VV- D 2S (Fig. 3C, lane 8) there
was inhibition of protein synthesis that could not be enhanced
by increased production of 2-5A (Fig. 3C, lanes 7 and 9). From
the results shown in Figure 3, we conclude that the ankyrin re-
gion in RNaseL is required for full endonuclease activity, and
the sequences responsible for activation by 2-5A map to ankyrin
repeats 6 to 9 of RNaseL.
Ankyrin domains 6 to 9 of RNaseL are required for
full induction of apoptosis by the 2-5A system
Next, we analyzed the influence of ankyrin domains in the
induction of apoptosis by the mutant forms of RNaseL. Thus,
BSC-40 cells were infected as before, low molecular weight
DNA was isolated at 48 h after infection, and DNA laddering
was analyzed by 1.6% agarose gel electrophoresis containing
0.1 m g/ml ethidium bromide in Tris-acetate/EDTA buffer. As
shown in Figure 4, cells infected with vT7 1 VV-RL presented
internucleosomal DNA fragmentation indicative of apoptosis
(Fig. 4, lane 3) that could not be observed in mock-infected
cells (Fig. 4, lane 1) or in cells infected with VV-2-5AS (Fig.
4, lane 2). DNA laddering was markedly increased by coex-
pressing 2-5A synthetase and RNaseL (Fig. 4, lane 4). Frag-
mentation of DNA was hardly detected in cells infected with
vT7 1 VV- D N (Fig. 4, lane 5), independently of coexpressing
2-5A synthetase (Fig. 4, lane 6). Interestingly, when 2-5A was
not produced in excess (in the absence of VV-2-5AS), the lev-
els of internucleosomal DNA fragmentation were similar be-
tween cells infected with vT7 1 VV- D 2S or vT7 1 VV-RL (Fig.
4, compare lanes 3 and 9) and lower in cells infected with
vT7 1 VV- D 1S (Fig. 4, compare lanes 3 and 8). However,
overproduction of 2-5A by coinfections of truncated forms of
RNaseL and VV-2-5AS did not enhance DNA ladder forma-
tion (Fig. 4, compare lanes 7 and 8, and 9 and 10, respec-
tively). These findings provide evidence that the ankyrin re-
peats 6 to 9 are required for full induction of apoptosis by the
2-5A system.
DISCUSSION
In this investigation, we have taken advantage of recombi-
nants of VV able to express as active forms the IFN-inducible
enzymes, RNaseL and 2-A synthetase. With the aim of identi-
fying domains of RNaseL important for its biological function,
we produced recombinant VV expressing truncated forms of
RNaseL and compared their properties with those of viruses
producing the full-length enzyme. Because deletion of a pro-
tein region may alter its stability or conformation or both and
indirectly affect the activity of this protein, some caution must
be exerted when analyzing results obtained with deletion mu-
tants. However, our conclusions using intact mammalian cells
basically confirm and extend results previously obtained using
in vitro expression systems.(15,32) In our in vivo assays, bind-
ing of 2-5A drives activation of RNaseL as an endoribonucle-
ase, which causes inhibition of protein synthesis, the probable
cause of inhibition of virus replication and of host cell death
by apoptosis. As index of biologic activity of the 2-5A system,
we evaluated endoribonuclease activity, inhibition of protein
synthesis, and induction of apoptosis. Although inducible by
IFN, basal levels of 2-5A synthetase are found in most, if not
all, mammalian cells (reviewed in Ref. 2), which are responsi-
ble for the accumulation late during VV infection of high lev-
els of 2-5A.(29,30) This oligonucleotide is able to partially acti-
vate exogenously produced recombinant RNaseL in
vT7 1 VV-RL-infected cells.(9) However, the enzyme can be
further activated if higher levels of 2-5A are produced by co-
expression of recombinant 2-5A synthetase. As observed in this
investigation, truncated forms of RNaseL have lower enzymatic
activity than full-length enzyme in the presence of excess 2-
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FIG. 4. Induction of apoptosis by coexpression of truncated
forms of RNaseL with 2-5A synthetase. Monolayers of BSC-
40 cells were either mock-infected (lane 1) or infected with the
indicated combinations of VV recombinant viruses (lanes 2±10)
for 48 h, as described in Figure 3. Low-molecular weight DNA
(3 3 106 cell equivalents per lane) was electrophoresed in an
agarose gel and stained with ethidium bromide.
5A, proving that binding of the oligonucleotide is a require-
ment for full activation of RNaseL in vivo. Moreover, the
ankyrin domain and, more precisely, amino acids 212±339
corresponding to part of repeat 6 and repeats 7 to 9 are criti-
cal for 2-5A regulation. Interestingly, this same region was
mapped before as the binding site of 2-5A by using an in vitro
assay performed with murine RNaseL-deleted protein.(15) Our
data support recent findings by Dong and Silverman(32) ob-
tained with mutant RNaseL expressed in E. coli. These au-
thors demonstrated that deletion of all nine ankyrin repeats in
RNaseL produced a protein with unregulated ribonuclease ac-
tivity similar to our results with RNaseL- D 2S. They have sug-
gested that in the absence of 2-5A, the ankyrin domain might
be interacting with the catalytic domain, blocking ribonucle-
ase activity and preventing dimerization by impeding access
to the sites involved in this interaction. Only after 2-5A is
bound is there a conformational change that allows dimer for-
mation rendering an active ribonuclease. Our results extend
the in vitro findings of Dong and Silverman(32) and demon-
strate in vivo that in the absence of all ankyrin repeats, the C-
terminal part of RNaseL is still biologically active, although
to a lesser extent than wild-type RNaseL, suggesting consti-
tutive activation of the enzyme. Full activation requires the
presence of ankyrin repeats 6 to 9, as revealed with the mu-
tant form of RNaseL- D 1S. That RNaseL- D 1S has enzymatic
activity, although lower than that of RNaseL- D 2S, suggests
that the modulatory domain is not fully comprised in ankyrin
repeats 6 to 9. It is not known if dimerization is required for
ribonuclease activity or is just a mechanism to maintain an
active conformation of RNaseL.
Our findings are also important to define the functionality
of ankyrin repeats. The fact that these sequences have been
found in functionally very diverse proteins from nearly all
phyla as well as in animal viruses(19) suggests that they do
not serve a highly specialized function. Current evidence sup-
ports the idea that this motif is involved in interactions be-
tween distinct proteins and within regions of a single protein
and, in some cases, in DNA binding.(33,34) Our results demon-
strate that by interacting with small oligonucleotides, ankyrin
repeats are key modulators of the biologic activity of pro-
teins.
The presence of the protein kinase domain in RNaseL
strongly suggests an additional level of regulation of the 2-5A
pathway throughout phosphorylation of different molecules of
RNaseL or other proteins that might be interacting with RNaseL
by the ankyrin repeats. Our expression system offers the op-
portunity to test these hypotheses.
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